Jun Liu

Jun Liu

Auto-generated profile, based on publicly available information

Jun Liu

Shanghai Ninth People’s Hospital 1 Department of Plastic and Reconstructive Surgery Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2023 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
LGLingling Ge
Lingling Ge
ZWZhi-Chao Wang
Zhi-Chao Wang
CWCheng-Jiang Wei
Cheng-Jiang Wei
JHJing-Xuan Huang
Jing-Xuan Huang
JLJun Liu
Jun Liu
QLQingfeng Li
Qingfeng Li

27 June 2024 in International Journal of Surgery
Verified
Journal Article
Open access
JHJingxuan Huang
Jingxuan Huang
HSHaoting Shi
Haoting Shi
LGLingling Ge
Lingling Ge
BZBeiyao Zhu
Beiyao Zhu
JLJun Liu
Jun Liu
ZWZhi-Chao Wang
Zhi-Chao Wang
An abstract is unavailable. This article is available as a PDF only.

11 February 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
ZWZhi-Chao Wang
Zhi-Chao Wang
JHJingxuan Huang
Jingxuan Huang
JLJun Liu
Jun Liu
YLYuehua Li
Yuehua Li
CWChengjiang Wei
Chengjiang Wei
QLQingfeng Li
Qingfeng Li
Purpose: Plexiform neurofibromas (PN) present a significant clinical challenge, with a notable unmet need for effective and well-tolerated therapies, particularly for the adult population. Patients and Methods: A single-arm, open-label, phase IIa trial of tunlametinib was conducted to assess its efficacy and safety in adults with inoperable, radiologically measurable PN. Patients received tunlametinib at a dose of 9 mg twice daily, following a continuous 21-day cycle regimen. The primary endpoint was the confirmed objective response rate (ORR), and secondary endpoints included disease control rate, duration of response, progression-free survival, and improvements in patient-reported outcomes (PRO) compared with baseline. Exploratory analyses integrating clinical variables and single-cell transcriptomic profiles were performed to explore response heterogeneity. Results: Of 15 adults (10 males and five females; median age, 27 years; range, 18–45), eight patients achieved a confirmed partial response, with an ORR of 53.3% (95% confidence interval, 26.69–78.73) and a median neurofibroma volume reduction of −23.5% (range, 1.6% to −49.1%). Significant improvements in multiple PRO domains were observed, including Patients’ Global Impression of Change and the Plexiform Neurofibromas Quality of Life scale. Regarding safety, all patients experienced at least one treatment-related adverse event, the majority of which were grade 1 or 2. Single-cell RNA sequencing profiling of pretreatment biopsies from one rapid responder and two gradual responders revealed substantial microenvironmental heterogeneity. Conclusions: Tunlametinib demonstrated promising efficacy and an acceptable safety profile in adults with PN, broadly aligning with the prior PN trials, including selumetinib and mirdametinib.



17 June 2026
Verified
Other
Open access
ZWZhi-Chao Wang
Zhi-Chao Wang
JHJingxuan Huang
Jingxuan Huang
JLJun Liu
Jun Liu
YLYuehua Li
Yuehua Li
CWChengjiang Wei
Chengjiang Wei
QLQingfeng Li
Qingfeng Li
Purpose:Plexiform neurofibromas (PN) present a significant clinical challenge, with a notable unmet need for effective and well-tolerated therapies, particularly for the adult population.Patients and Methods:A single-arm, open-label, phase IIa trial of tunlametinib was conducted to assess its efficacy and safety in adults with inoperable, radiologically measurable PN. Patients received tunlametinib at a dose of 9 mg twice daily, following a continuous 21-day cycle regimen. The primary endpoint was the confirmed objective response rate (ORR), and secondary endpoints included disease control rate, duration of response, progression-free survival, and improvements in patient-reported outcomes (PRO) compared with baseline. Exploratory analyses integrating clinical variables and single-cell transcriptomic profiles were performed to explore response heterogeneity.Results:Of 15 adults (10 males and five females; median age, 27 years; range, 18–45), eight patients achieved a confirmed partial response, with an ORR of 53.3% (95% confidence interval, 26.69–78.73) and a median neurofibroma volume reduction of −23.5% (range, 1.6% to −49.1%). Significant improvements in multiple PRO domains were observed, including Patients’ Global Impression of Change and the Plexiform Neurofibromas Quality of Life scale. Regarding safety, all patients experienced at least one treatment-related adverse event, the majority of which were grade 1 or 2. Single-cell RNA sequencing profiling of pretreatment biopsies from one rapid responder and two gradual responders revealed substantial microenvironmental heterogeneity.Conclusions:Tunlametinib demonstrated promising efficacy and an acceptable safety profile in adults with PN, broadly aligning with the prior PN trials, including selumetinib and mirdametinib.